Stryker Co. (NYSE:SYK) is Stonehage Fleming Financial Services Holdings Ltd’s 10th Largest Position

Stonehage Fleming Financial Services Holdings Ltd trimmed its stake in shares of Stryker Co. (NYSE:SYK) by 4.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 453,104 shares of the medical technology company’s stock after selling 20,366 shares during the quarter. Stryker makes up 4.6% of Stonehage Fleming Financial Services Holdings Ltd’s investment portfolio, making the stock its 10th largest position. Stonehage Fleming Financial Services Holdings Ltd’s holdings in Stryker were worth $163,140,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of SYK. Zhang Financial LLC boosted its stake in Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after purchasing an additional 40,784 shares during the last quarter. Dale Q Rice Investment Management Ltd acquired a new position in Stryker during the fourth quarter worth about $587,000. PFW Advisors LLC purchased a new stake in Stryker during the 4th quarter valued at about $1,350,000. Parnassus Investments LLC acquired a new stake in Stryker in the 3rd quarter valued at about $762,798,000. Finally, Traynor Capital Management Inc. purchased a new position in Stryker in the 4th quarter worth approximately $324,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SYK. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Needham & Company LLC restated a “buy” rating and set a $442.00 price objective on shares of Stryker in a research report on Tuesday, January 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $425.00 target price on shares of Stryker in a research note on Tuesday, January 7th. JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Finally, Barclays raised their price objective on Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $405.80.

Stryker Stock Performance

Shares of Stryker stock opened at $394.08 on Monday. The business has a 50-day simple moving average of $376.11 and a 200-day simple moving average of $360.98. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a one year low of $307.23 and a one year high of $398.20. The company has a market cap of $150.23 billion, a PE ratio of 42.24, a P/E/G ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.46 EPS. On average, equities research analysts forecast that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. Stryker’s payout ratio is 36.01%.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.